Back to Search
Start Over
Boosting bioavailability of topotecan: what do we gain?
- Source :
-
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2002 Jul 01; Vol. 20 (13), pp. 2918-9. - Publication Year :
- 2002
- Subjects :
- ATP Binding Cassette Transporter, Subfamily G, Member 2
Administration, Oral
Antineoplastic Agents administration & dosage
Biological Availability
Breast Neoplasms drug therapy
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Enzyme Inhibitors administration & dosage
Female
Humans
Intestinal Absorption drug effects
Neoplasm Proteins antagonists & inhibitors
Topotecan administration & dosage
ATP Binding Cassette Transporter, Subfamily B, Member 1 antagonists & inhibitors
ATP-Binding Cassette Transporters antagonists & inhibitors
Acridines pharmacology
Antineoplastic Agents pharmacokinetics
Breast Neoplasms metabolism
Enzyme Inhibitors pharmacokinetics
Isoquinolines pharmacology
Tetrahydroisoquinolines
Topoisomerase I Inhibitors
Topotecan pharmacokinetics
Subjects
Details
- Language :
- English
- ISSN :
- 0732-183X
- Volume :
- 20
- Issue :
- 13
- Database :
- MEDLINE
- Journal :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 12089219
- Full Text :
- https://doi.org/10.1200/JCO.2002.20.13.2918